India's Sun Pharmaceuticals has commenced its tender offer to acquire all outstanding ordinary shares of Israel's Taro following the bitter collapse of the firms' merger agreement (Marketletter June 9).
Sun's subsidiary Alkoloida is tendering the offer for the same cost as the merger (Marketletter May 28, 2007), $7.75 per share, under an option laid out in the terms of that deal. Taro's withdrawal from the agreement is being challenged by Sun in the New York State Supreme Court of the USA.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
7 day trial access
Become a subscriber
Or £77 per month
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Copyright © The Pharma Letter 2025 | Headless Content Management with Blaze